There are several striking things about Sarepta’s FDA approval this week for its controversial and long-delayed DMD drug, but just how it gained approval from…

Sarepta added more than 75% in early trading on news that its Duchenne muscular dystrophy (DMD) treatment Exondys 51 has been approved.

Just over a month before the presidential elections and in his last few weeks as vice president, Joe Biden is looking to cement his so-called Cancer Moonshot…

Novartis released updated data for its MS candidate siponimod (aka BAF312) over the weekend which showed it can cut the risk of patients’ disability…

Novo Nordisk has shown that its once-weekly experimental injectable diabetes med semaglutide can cut a number of cardiovascular events by 26% in Type 2…

Novavax saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks…

An influential group of experts from the FDA has said that small cap Spectrum’s experimental bladder cancer med Qapzola (apaziquone) isn’t good enough for…

Roche’s new multiple sclerosis drug has beaten out the aging MS treatment Rebif (interferon beta-1a) in a head-to-head late-stage test as it looks to a…